Objective Satellite cells(SCs) transplant was tried to treat myocardium infarction(MI) in human.Methods 10 patients who affected by coronary artery disease(CAD) and MI were selected.A piece of muscle was taken away from their quadriceps femoris 2 weeks before surgical operation.SCs were extracted,purified,cultured by modified Dorfman method,and then transplanted into the MI area by intramyocardial injection after CABG.EKG,UCG,99cTc-SPECT cardiac blood pool imaging,18F-FDG myocardial perfusion imaging were examined before operation and 3 months after operation.The cell metabolism status in the MI area were observed and LVEF were measured and analyzed by paired-samples t test with SPSS13.0 statistics software.Results After cultured in vitro for3 days,SCs were spindleshaped,and sticked to walls.SCs growth was stasis,fused into each other,and formed myotube when the cells were delayed to divide Petri dish or the concentration of fetus bovine serum(FBS) in the culture medium was reduced.Average 2.7 blood vessel bypass were established in these patients.SCs were transplanted merely in one patient whose coronary arteries were extensively sclerosed.No patients died in hospital.Heart function of these patients were recovered to NYHA I 3 months after operation.Their symptoms of angina pectoris were disap peared and quality of life was improved obviously.The cell metabolism activity was appeared again in the MI area 3 months after operatio(including the patient without CABG).LVEF were increased(9.70±4.17)% than preoperation.There is significant deviation between them(P<0.01).Conclusions Autograft of SCs can be alive in the MI area,and SCs can improve the heart function by participating the heart's systole and diastole activity directly or by altering cardiac compliance and stimulating the blood capillary proliferation.

Objective To investigate the safety and efficacy of sirolimus-based immunosuppression therapy in liver transplantation. Methods Immunosuppression in 12 patients after liver transplantation was converted from calcineurin Inhibitor (CNI) to sirolimus for at least one month. Safety evaluations consisted of regular measurements of serum creatinine and liver enzymes to assay the restoration of CNI related nephrotoxicity and hepatoxicity. Efficacy analysis was performed by biopsy to evaluate the rejection incidence. Results The patients were followed up for a mean of 37 months after liver transplantation. Immunosuppression therapy was converted after a mean of 11 months. The average sirolimus conversion therapy period was 14 months. Among 12 patients experiencing sirolimus conversion therapy, 6 did not develop rejection on biopsy. Among 7 patients with CNI-related nephrotoxicity, 5 showed the restoration of serum creatinine to normal but1 developed albuminuria. All four patients with mild liver dysfunction did not improve. Conclusion The conversion from CNI to sirolimus is treatable based on liver biopsy in some selected liver transplant recipients,

Recently, the clinical trials of combined immunotherapy for advanced hepatocellular were completed successfully (Imbrave150, Keynote524), which have significantly increased the objective response rate and prolonged median overall survival time. The success of combined immunotherapy provides great potential and reality for subsequent surgical intervention of advanced hepatocellular carcinoma. Nowadays, the hot topics of combined immunotherapy include the choices of combined immunotherapy, the perioperative period determination, tumor immune microenvironment, and effective biomarkers of immunotherapy selection, and so on. This paper intends to summarize the above-related issues.

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a new surgical management which brings hopes of cure to patients with primary or metastatic liver tumor who do not have sufficient future liver remnant (FLR).This review summarizes the current research on the development,indication,surgical procedures and safety of ALPPS.It also discusses the major concerns and unanswered doubts of ALPPS,such as the comparison with selective portal vein embolization (PVE) and the long-term oncological progression.

Objective To investigate the etiology and management of early postoperative hyperbilirubinemia after liver transplantation. Methods The etiology and dynamic alteration of early postoperative hyperbilirubinemia in 50 liver transplants were retrospectively analyzed by a comparative trial of clinical manifestation with serial liver biopsy. Results The total serum bilirubin (TB) level profile presented like a invert "S" curve. At the first week, second week and 4th week after liver transplantation the serum TB levels were in average ( 127.19? 113.15)? ( 135.45? 124.6) and ( 73.1? 49.52)??mol/L respectively. Three months later, the serum TB level approximated to normal TB level ( 29.8? 37.56)??mol/L. The dynamic alternations of total serum bilirubin level were incorporated with the morphological improvement under microscopy of liver allograft following liver transplantation. The initial hyperbilirubinemia of reciepient before liver transplantation (10 cases, 20?%), preservation injury (containing 44 cases of ischemic reperfusion injury, 88?%), acute cellular rejection (13 cases, 26?%) and bile duct leakage (4 cases, 8?%) were 4 essential causes responsible for the early postoperative hyperbilirubinemia. The total serum bilirubin level profile was not characteristic of each catergory. Those 4 casuses mentioned above presented either independently or concomitantly in concrete case. No primary hepatic failure (PHF) occurred and curability of hyperbilirubinemia was about 100?% in our series. Furthermore, the perioperative survival rate of the recipients and liver allograft was 90.6?% and 1-year accumulative survival rate was about 80?%.Conclusions The hyperbilirubinemia is common clinical manifestion within 3 months after liver transplantation. Preservative injury, acute rejection, preoperative hyperbilirubinemina and bile duct leakage are four essential causes. The comprehensive management targeted to etiology can usually achieve a good outcome for the reciepients with hyperbilirubinemia.

Objective To investigate the effect of liver transplantation on extensive intrahepatic duct stones with biliary cirrhosis and unresectable intrahepatic alveolar echinococcosis.Methods Orthotopic liver transplantation was performed on 2 patients with extensive intrahepatic stones with biliary cirrhosis and 4 cases of unresectable alveolar echinococcosis. The pre- and intraoperative condition and postoperative complications were evaluated. All patients were regularly followed up. Results Two patients with intrahepatic stones have survived for more than 2 years after the transplantation. Three of 4 patients with alveolar echinococcosis have survived for 9, 15 months and 2 years respectively, up to now. Another one died of heart failure at the postoperative 3rd month. All survivors have recovered well their normal life and work. Conclusion Liver transplantation could be regarded as effective therapeutic means for extensive intrahepa- tic stones and unresectable alveolar echinococcosis.

Objective To investigate the preventions and managements of hepatic artery reconstructions and its complications. Method Seventy-two patients who underwent the reconstruction of hepatic artery in orthotopic liver transplantation (OLT) and were followed up during recent 3 years after OLT were collected and analyzed retrospectively. Results The overall hepatic artery complications rate was 1.4 % (1/72). A pseudoaneurysm at the side of hepatic artery anastomosis was found by angiography and embolized successfully. The patency of hepatic artery toward donor liver was remained. Postoperative Doppler ultrasonography monitoring showed that no hepatic arterial thrombosis and stenosis occurred during 43 months of follow-up after OLT. Six patients died in the hospital after OLT and 6 patients died during the follow-up period. The overall cumulative 1-, 3-year survival rate was 83.3 % and 83.3 % respectively. No death associated with hepatic artery complications occurred. Conclusion Complete evaluation and prompt management perioperatively of hepatic artery reconstruction and its complications may improve the long-term survival of the recipients and grafts after OLT.

Objective Satellite cells(SCs) transplantation was tried to improve cardiac function in this experiment.Methods A myocaridium infarction was created in 23 male Suzhong pigs by ligating the diagonal ramus,and the alive pigs were divided into the experimental group and the control group.SCs were extracted,purified,cultured by modified Dorfman method,and were transplanted into myocardium by intramyocardial injection.By pathomorphological research,we observed the therapeutic outcomes of heart failure.Results ⑴10 pigs were alive(5 in the control group,and the other 5 in the experimental group).The successful rate of making mould was 43 5%.⑵After cultured in vitro for 3 days,SCs were spindle-shaped,and sticked to walls.SCs growth were stasis and each other fusing into form myotube when we delayed to divede Petri dishs or reduced the concentration of Fetus Bovine Serum(FBS) in the culture medium.⑶In the experimental group,neonate skeletal muscle cells were observed in the infarction regions,which were multi-nuclei near edges.These cells aligned in an accordance direction.Intercalated disks were not found between them.The capillary density in experimental group was much higher than the control group.Conclusions Autograft of SCS can be alive in acceptor,and improve the heart function by altering cardiac compliance and configuration,or by stimulating the blood capillary proliferation.SCs don't form intercalated disks with remnant myocardial cells,so synchro-contraction will not occur between them,but malign arrhythmia are not found.

Objective To investigate the common reasons,prophylaxes and treatment of postoperative complications in orthotopic liver transplantation (OLT).Method Seventy two patients who underwent OLT during recent three years were collected and analyzed retrospectively.Results OLT was performed on 50 cases with benign diseases including terminal liver cirrhosis 34;and 22 cases with and malignant diseases including hepato cellular carcinoma 19 cases.Fifty four complications were occurred postoperatively,including secondary abdominal cavity bleeding (4 cases ),severe infection of ascites (2 cases),stress gastric ulcer with bleeding and perforation (1 cases),biliary leak (6 cases),pulmonary infection (21 cases),and enteric fungal infection (5 cases).There were no primary dysfunction of liver and vascular complications.Follow up 2-41 months, without biliary complications and chronic liver dysfunction occurred 6 cases death postoperative,6 cases death on follow-up period.Total surrival rate is 83.33%, 32 cases alive more than 1 year,the longest surrival cases is 41 months postoperative.Conclusions It is suggested that the cases with cirrhosis are main indication for liver transplantation.The patients with liver cirrhosis always combinated of liverdisfunction,coagulopaphy,malnutrition and poor immune functions and we should pay attention to replace that of coagulation factors,antibiotics using and nutrition support perioperatively.Good surgical technique is the key point for preventing vascular complications.

ObsjectiveTo investigate the clinical data,and to summarize the clinical experience of diagnosis and treatment of graft-versus-host-disease (GVHD) after liver transplantation.Methods 4 of 480 recipients undergone liver transplantation developed GVHD from Apr.2005 to Sep.2011.The 4 recipients'clinical courses and laboratory tests were recorded.ResultsThe diagnosis of GVHD depended on clinical syndrome involved skin rash,bone marrow depression and diarrhea.Skin biopsy and STR-PCR were matched.Among them,2 with successful treatment have been surviving for 7 and 24 months,and 2 died from infection.One recipient had the donor T lymphocyte microchimerism detected by STR-PCR.ConclusionsGVHD after liver transplantation can cause high mortality due to bone marrow depression.A reasonable treatment can be to reduce immunosuppressant and glucocorticoids and IVIG.